Abstract
There is an ongoing interest of having a somatostatin analog radiotracer labeled with 18F for PET imaging of neuroendocrine tumors. Nonetheless, there is none yet approved for clinical use. 18F is the ideal radionuclide for PET imaging due to its high β+ decay, suitable half-life and ease of production. As with other peptides, the labeling of SSTA with 18F comes along with its complications. In this review, we discuss the methods to label SSTA with 18F highlighting the chemistry as well as an overview in the progress on preclinical and clinical applications of 18F-labeled SSTA tracers.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
